

Effects of Angiotensin-Converting Enzyme Inhibition and Statin Treatment on Inflammatory Markers and Endothelial Functions in Patients with Longterm Rheumatoid Arthritis

CANAN TIKIZ, OZAN UTUK, TIMUR PIRILDAR, OZGUR BAYTURAN, PETEK BAYINDIR, FATMA TANELI, HAKAN TIKIZ, and CIGDEM TUZUN

ABSTRACT. Objective. To investigate the effects of angiotensin-converting enzyme (ACE) inhibitors and statins (hydroxy-methyl-glutaryl-CoA reductase inhibitors) on inflammatory markers and endothelial functions in patients with rheumatoid arthritis (RA).

Methods. A total of 45 patients with longterm RA were randomized into 3 groups to receive 8 weeks of treatment with placebo (n = 15), simvastatin (20 mg/day, n = 15), or quinapril (10 mg/day, n = 15) as an adjunct to existing antirheumatic drug treatment. Factors with a role in the development of endothelial dysfunction, such as C-reactive protein (CRP), fibrinogen, nitric oxide (NO), and serum cytokine concentrations including interleukin 1 β (IL-1 β), IL-6, and tumor necrosis factor- α (TNF- α) were measured at baseline and in the posttreatment period. Brachial artery vasodilator responses were assessed by high resolution ultrasound to evaluate endothelial functions.

Results. Simvastatin treatment significantly decreased serum CRP and TNF- α [from 14 ± 6 to 7 ± 3 mg/l (p = 0.025) and 30 ± 5 to 16 ± 4 pg/ml (p = 0.012), respectively], while quinapril had no significant changes in these 2 measures. IL-1 β and IL-6 showed insignificant changes in patients in the 2 drug groups. Endothelium-dependent vasodilatation was improved significantly in the simvastatin group [from $5.3 \pm 1.1\%$ to $8.9 \pm 1.4\%$ (p = 0.025)], while there was no difference in endothelium-independent vasodilatation [$9.0 \pm 1.8\%$ to $11.2 \pm 2.5\%$ (p = 0.17)]. The quinapril group showed no significant changes in both types of vasodilatation although there was a tendency to an increase in endothelium-dependent vasodilatation [from $6.1 \pm 0.8\%$ to $7.8 \pm 0.7\%$ (p = 0.06)]. Treatment with the 2 drugs had no significant effects on resting arterial diameter.

Conclusion. We show that simvastatin 20 mg daily improves endothelial function in patients with RA. Its beneficial effect may be attributed to lowering CRP and TNF- α concentrations. ACE inhibition with daily 10 mg quinapril was found to have no significant effects on inflammatory markers and endothelial vasodilator response. (J Rheumatol 2005;32:2095–101)

Key Indexing Terms:

RHEUMATOID ARTHRITIS ENDOTHELIAL FUNCTION INFLAMMATORY MARKERS
STATIN ANGIOTENSIN-CONVERTING ENZYME INHIBITOR

Endothelial dysfunction is widely accepted as a key process in atherosclerosis and independently predicts cardiovascular mortality^{1,2}. It denotes impairment of endothelium-dependent vasodilatation and is associated with advanced age,

hypercholesterolemia, cigarette smoking, hypertension, diabetes mellitus, high homocysteine concentrations, and inactivity³. While the precise mechanism remains to be elucidated, endothelial dysfunction appears to develop after a short or transient period of an inflammatory process⁴.

It is well documented that the number of cardiovascular events in patients with rheumatoid arthritis (RA) was 4 times higher than in individuals of the same age and sex without RA⁵. The increased prevalence of cardiovascular complications in patients with RA is closely related to the presence of atherosclerosis, and accelerated atherogenesis is shown to be the major cause of morbidity and mortality in this group⁶. In the rheumatic diseases, endothelial dysfunction has been described in states of necrotizing vasculitis, where the vessel wall is the primary target of the pathological process⁷. RA, however, primarily affects the diarthrodial joints and not the vasculature. Nonetheless, many recent

From the Department of Physical Medicine and Rehabilitation, Department of Cardiology, Department of Internal Medicine, Division of Rheumatology, Department of Radiology, and Department of Clinical Biochemistry, University of Celal Bayar, Faculty of Medicine, Manisa, Turkey.

C. Tikiz, MD, Assistant Professor; Ç. Tüzün, MD, Professor, Department of Physical Medicine and Rehabilitation; O. Ütük, MD, Assistant Professor; Ö. Bayturan, MD, Assistant Professor; H. Tikiz, MD, Associate Professor, Department of Cardiology; T. Pirildar, MD, Assistant Professor, Division of Rheumatology; P. Bayindir, MD, Assistant Professor, Department of Radiology; F. Taneli, MD, Department of Clinical Biochemistry.

Address reprint requests to Dr. C. Tikiz, 1748 sokak, 26/4, 35530 Karsiyaka, Izmir, Turkey. E-mail: canan.tikiz@bayar.edu.tr
Accepted for publication June 14, 2005.

studies describe endothelial dysfunction in patients with RA⁸⁻¹¹ that could be reversed with anti-tumor necrosis factor- α (TNF- α) treatment^{12,13}.

In addition to anti-TNF- α treatment, angiotensin-converting enzyme (ACE) inhibitors¹⁴⁻¹⁶ and hydroxy-methylglutaryl-CoA reductase (HMG CoA) inhibitors (statins)¹⁷⁻²⁰ were shown to improve endothelial dysfunction in patients with high cardiovascular risk. However, to date there are limited data on the effects of statins and ACE inhibitors on endothelial functions in patients with RA.

We investigated and compared the effects of ACE inhibition with quinapril and hydroxy-methylglutaryl-CoA reductase (HMG CoA) inhibition with simvastatin on endothelial functions determined by flow mediated and glycerol trinitrate (GTN) induced vasodilatation using high-sensitivity brachial ultrasonography in patients with longterm RA. We also evaluated the inflammatory markers that may have an important role in development of endothelial dysfunction, including fibrinogen, C-reactive protein (CRP), nitric oxide (NO), and cytokines such as interleukin 1 β (IL-1 β), IL-6 and tumor necrosis factor- α (TNF- α).

MATERIALS AND METHODS

Patient population. In this randomized, placebo controlled study, 45 patients with longterm RA (41 women, 4 men, mean age 48 yrs, mean disease duration 8.7 yrs) recruited from Celal Bayar University between September 2003 and July 2004 were included. Patients fulfilled the 1987 American Rheumatism Association criteria for RA and were receiving disease modifying antirheumatic drugs (DMARD) with and without steroids and nonsteroidal antiinflammatory drugs (NSAID)²¹. Baseline variables included demographic characteristics and disease duration; the Disease Activity Score (DAS28) was obtained from 28-joint counts as described²². We also recorded patients' DMARD use from their charts.

Patients were excluded for the following reasons: history of coronary bypass grafting, myocardial infarction within 28 days, left ventricular dysfunction (ejection fraction < 40%), total cholesterol > 240 mg/dl, uncontrolled hypertension (> 160/95 mm Hg), significant valvular heart disease, type I diabetes mellitus, or smoking within 6 months before screening. Patients were also excluded if they had received any kind of ACE inhibitor or angiotensin II receptor blockers within 6 months of randomization; or had had treatment with any lipid-lowering agents, hormone replacement therapy, or antioxidant therapy within 3 months. All patients signed a written consent form after being informed about the details of the study.

Study protocol. Subjects were randomly assigned to one of 3 groups. Group I received placebo (n = 15), Group II received simvastatin 20 mg/day (n = 15), and Group III received quinapril 10 mg/day (n = 15) for 8 weeks. Preexisting DMARD treatment and diet remained unchanged throughout the study course. One patient from the quinapril group and one patient from the simvastatin group did not continue the study because of symptomatic hypotension and muscle weakness, respectively. The remaining 43 patients all completed the study.

Biochemical analysis. Blood samples were drawn into plain tubes between 7 and 10 A.M. after fasting roughly 12 h. Serum samples were obtained and frozen at -20°C. Total cholesterol, glucose, triglycerides, HDL cholesterol, LDL cholesterol, urea, creatinine, serum alanine aminotransferase, serum aspartate aminotransferase, calcium, phosphorus, apolipoprotein A (apo A), apolipoprotein B (apo B), and lipoprotein(a) [Lp(a)] were assessed by enzymatic methods (Integra Roche Diagnostics, Indianapolis, IN, USA) with commercial reagents. CRP levels were measured by nephelometry analyzer (Dade-Behring, Deerfield, IL, USA).

High-sensitivity solid phase ELISA kits were used to measure serum IL-1 β , IL-6, and TNF- α (BioSource International, Camarillo, CA, USA) levels. Sensitivity for the minimum detectable dose for IL-1 β is 1 pg/ml, and intraassay precision (coefficient of variation, CV) is 4.7% at 194.9 pg/ml, 4.1% at 101.6 pg/ml, and 4.5% at 60.2 pg/ml. Interassay precision, CV, of IL-1 β is 6.9% at 193.8 pg/ml, 6.0% at 101.8 pg/ml, and 7.3% at 56.3 pg/ml. Sensitivity of the minimum detectable dose of IL-6 is < 2 pg/ml, and intraassay coefficient of variation is 7.7% at 38.8 pg/ml, 5.7% at 101.2 pg/ml, and 5.1% at 242.7 pg/ml. Interassay CV of IL-6 is 9.3% at 35.3 pg/ml, 6.5% at 97.4 pg/ml, and 7.8% at 236.7 pg/ml. Sensitivity of the minimum detectable dose for TNF- α is 1.7 pg/ml, and intraassay CV is 5.2% at 58.0 pg/ml, 4.1% at 167.0 pg/ml, and 3.9% at 459 pg/ml. Interassay CV of TNF- α is 8.5% at 47.0 pg/ml, 8.2% at 170.0 pg/ml, and 5.9% at 438 pg/ml. Serum NO levels were assessed by the Griess method²³. All assays were performed in duplicate by technicians blinded to diagnosis.

Assessment of endothelial function. Patients were studied in the morning, between 9:00 and 11:00 AM, in a quiet room with a temperature of 20-24°C, after an overnight fast. Each patient avoided alcohol, caffeine, and cigarette smoking the night before, and all additional drug treatment (simvastatin, quinapril, and placebo) was withheld for at least 24 h before the second test. The subject lay at rest for at least 10 min before a first resting screen was recorded. Flow-mediated dilatation and GTN-induced vasodilatation (0.4 mg sublingual Nitrolingual spray; Pohl-Boskamp, Hohenlockstedt, Germany) of the brachial artery was determined by high-resolution ultrasound with a 7.5 MHz linear array transducer (Siemens Sonoline Electra) according to a validated method²⁴ by the same physician (PB), who was blinded to patient data. Briefly, the arterial diameter was measured at a fixed distance from an anatomical marker such as a bifurcation and calculated as the mean value of 2 measurements at the end of the diastole, concurrent with the onset of the QRS complex. The average diameter of the artery then was calculated over 3 cardiac cycles. After taking the baseline measurements, increased flow was induced by inflation of a brachial cuff placed on the proximal limb and inflated to a pressure of 50 mm Hg above systolic pressure for 5 min. After release, the arterial diameter was recorded every 15 s for 3 min. Post-test arterial diameter measurements were made 60 s after cuff deflation. Fifteen minutes was allowed for vessel recovery before GTN application, and the same procedure was repeated after GTN application. To evaluate the reproducibility of imaging and to assess intraobserver variability, a second assessment was done for the same patients on consecutive days in 15 randomly selected patients, and the stored images were then analyzed offline blinded to patients' details.

The correlation coefficients were $r = 0.92$ for baseline, $r = 0.94$ for reactive hyperemia, and $r = 0.90$ for GTN induced vasodilatation.

Statistical analysis. SPSS v. 11.0 was used for statistical analysis. Data are expressed as mean \pm standard error (SEM). Baseline characteristics were compared using the Mann-Whitney U test or chi-square test, as appropriate. Differences and percentage changes in baseline characteristics and biochemical markers between the 3 groups in the pre- and posttreatment periods were investigated by Kruskal-Wallis test, and post-hoc analyses were performed using Mann-Whitney U tests. Wilcoxon rank test was used for paired comparisons. Percentage changes in vasodilatory responses were calculated as [(posttreatment value - pretreatment value)/pretreatment value \times 100]. P values < 0.05 were considered to be significant.

RESULTS

The baseline demographics and clinical characteristics of the patients are summarized in Table 1. The groups were matched in terms of age, sex, body mass index, and cardiovascular risk factors such as hypertension and diabetes mellitus. Disease Activity Scores (DAS28) and the RA treatment protocols were also similar to each other. Table 2 shows basal clinical measures such as mean arterial pres-

Table 1. Demographic variables and baseline characteristics of patients. Data are given as mean \pm standard error of mean (SEM).

	Placebo, n = 15	Simvastatin, 20 mg/day, n = 14	Quinapril, 10 mg/day, n = 14
Disease duration, yrs	8 (2)	10 (3)	8 (2)
Rheumatoid factor positive, %	100	90	80
DAS28	4.57 (1.5)	4.60 (1.65)	4.59 (1.16)
Age, yrs	48 (10)	46 (8)	50 (10)
Male/female	1/9	2/9	1/10
BMI, kg/m ²	27 (1.2)	25 (1)	26 (2)
Creatinine, mg/dl	0.74 (0.08)	0.82 (0.13)	0.69 (0.11)
Hypertension, n (%)*	2 (13)	3 (21)	3 (21)
Diabetes mellitus, n (%)*	2 (13)	3 (21)	2 (14)
Treatment, (%)			
Corticosteroids	100	100	100
NSAID	100	100	100
Methotrexate	16	14	14
Sulfasalazine	66	71	57
Leflunomide	33	35	28

No significant differences were noted between baseline characteristics, risk factors, and medications between groups. BMI: body mass index, DAS: Disease Activity Score, NSAID: nonsteroidal antiinflammatory drug. * Under control with drug treatment.

Table 2. Basal values of mean arterial pressure (MAP) and biochemical markers of patients. Data are mean \pm standard error of mean (SEM).

	Placebo, n = 15	Simvastatin, 20 mg/day, n = 14	Quinapril, 10 mg/day, n = 14	p
MAP, mm/Hg	89 (1.9)	91 (2.4)	90 (2.2)	0.89
Fibrinogen, mg/l	375 (31)	426 (54)	361 (48)	0.45
CRP, mg/l	12 (3)	14 (6)	10 (2)	0.72
Total cholesterol, mg/dl	210 (6)	234 (12)	216 (8)	0.21
LDL cholesterol, mg/dl	122 (8)	130 (12)	126 (11)	0.10
Triglyceride, mg/dl	138 (13)	149 (32)	148 (29)	0.90
Lp(a), mg/dl	35 (10)	37 (8)	24 (6)	0.65
NO, μ mol/l	41 (2)	42 (3)	44 (5)	0.61
Apo-A, g/l	1.5 (0.04)	1.6 (0.11)	1.5 (0.06)	0.18
Apo-B, g/l	0.58 (0.05)	0.76 (0.06)	0.71 (0.07)	0.07
Cytokines				
IL-1 β , pg/ml	4.8 (0.7)	6.3 (1.7)	4.0 (0.8)	0.10
IL-6, pg/ml	17 (8)	18 (8)	14 (4)	0.40
TNF- α , pg/ml	27 (4)	30 (5)	27 (4)	0.65

CRP: C-reactive protein, NO: nitric oxide, LDL: low density cholesterol, Lp(a): lipoprotein(a), Apo-A: apolipoprotein-A, Apo-B: apolipoprotein-B, IL-1 β : interleukin 1 β , TNF: tumor necrosis factor.

sure, fibrinogen, CRP, NO, lipid measurements, and cytokine levels. As shown, all measures were similar among the 3 groups. Table 3 summarizes percentage changes between pre- and posttreatment values. The quinapril group showed decreased mean arterial pressures compared to the other groups, as expected. Total cholesterol and LDL cholesterol were significantly decreased in the simvastatin group compared to others. Changes in Lp(a), apo-A, apo-B, and NO were similar in the simvastatin and quinapril groups and showed no statistical differences ($p > 0.05$). Simvastatin treatment significantly decreased serum CRP and TNF- α

levels: from 14 ± 6 to 7 ± 3 mg/l ($p = 0.025$) and 30 ± 5 to 16 ± 4 pg/ml ($p = 0.012$), respectively; while no significant changes were observed in the quinapril group. IL-1 β and IL-6 showed insignificant changes in both the simvastatin and quinapril groups. Table 4 illustrates the percentage changes in endothelium-dependent and independent vasodilatation in placebo, simvastatin, and quinapril groups. Endothelium-dependent vasodilatation was improved significantly in the simvastatin group (from $5.3\% \pm 1.1\%$ to $8.9\% \pm 1.4\%$; $p = 0.025$), while there was no difference in endothelium-independent vasodilatation ($9.0\% \pm 1.8\%$ to $11.2\% \pm 2.5\%$;

Table 3. Mean percentage (%) changes in mean arterial pressure and biochemical markers after 8 weeks of treatment.

	Placebo, n = 15	Simvastatin, n = 14	Quinapril, n = 14	p*
MAP, mm/Hg	2.2↓ ^{b,c}	1.8↑	10↓	0.024
Fibrinogen, mg/l	7↓	25↓	8↓	0.75
CRP, mg/l	12↓ ^{a,c}	50↓	20↓	0.035
Total cholesterol, mg/dl	7↑ ^{a,c}	18↓	4↑	0.030
LDL cholesterol, mg/dl	2↑ ^{a,c}	16↓	3↑	0.018
Triglyceride, mg/dl	14↑	7↓	2↑	0.90
Lp(a), mg/dl	18↓	11↓	13↑	0.65
NO, μmol/l	7↓	10↑	15↑	0.61
Apo-A, g/l	7↓	6↓	7↑	0.18
Apo-B, g/l	29↑	13↓	18↓	0.07
Cytokines				
IL-1, pg/ml	7↓	31↓	3↑	0.95
IL-6, pg/ml	8↓	25↓	26↓	0.94
TNF-α, pg/ml	7↓ ^{a,c}	46↓	15↓	0.03

Abbreviations as in Table 2. ^a Variables of placebo group are significantly different from simvastatin group. ^b Variables of placebo group are significantly different from quinapril group. ^c Variables of simvastatin group are significantly different from quinapril group. * Kruskal-Wallis test. ^{a,b,c} Post-hoc analysis with Mann-Whitney U test.

Table 4. Changes in endothelial functions of both groups of patients at baseline and after 8 weeks of treatment. Data are mean ± standard error of mean (SEM).

	Placebo, n = 15		Simvastatin, 20 mg/day, n = 14		Quinapril, 10 mg/day, n = 14	
	Basal	Posttreatment	Basal	Posttreatment	Basal	Posttreatment
Arterial diameter, mm	3.3 (0.7)	3.4 (0.5)	3.2 (0.4)	3.1 (0.4)	3.4 (0.5)	3.4 (0.4)
Flow mediated vasodilatation, %	5.7 (1.3)	5.9 (1.2)	5.3 (1.1)	8.9 (1.4)*	6.1 (0.8)	7.8 (0.7)
GTN-induced vasodilatation, %	9.7 (2.1)	9.9 (1.8)	9.0 (1.8)	11.2 (2.5)	8.9 (1.4)	10.3 (1.8)

GTN: glycerol trinitrate. * P = 0.025 compared to basal value.

p = 0.17) (Figures 1 and 2). The quinapril group showed no significant changes in these responses, although there was a tendency to an increase in endothelium-dependent vasodilatation (from 6.1% ± 0.8% to 7.8% ± 0.7%; p = 0.06). Treatment with each drug had no significant effects on resting arterial diameter.

DISCUSSION

The novel finding of our study was that treatment with simvastatin 20 mg daily for 2 months significantly improved endothelial-dependent vasodilatation in patients with longterm RA under conventional antirheumatic drug treatment, while no significant change was observed with quinapril 10 mg daily. Simvastatin was also shown to decrease the inflammatory markers including CRP and TNF-α significantly, while the placebo and quinapril groups showed no significant changes in any measured inflammatory marker.

Increased prevalence of cardiovascular morbidity and

mortality due to premature atherosclerosis has been observed in patients with autoimmune diseases such as RA and systemic lupus erythematosus^{25,26}. The mechanisms that cause acceleration in the atherosclerotic process in this patient group are still under investigation. Recent reports describe that endothelial dysfunction is one of the main factors involved in this pathological process²⁷. Inflammatory mechanisms implicated in the development of synovial lesions in RA have been suggested to involve the vessel wall and to initiate the development of atherosclerosis²⁸, and many recent studies describe endothelial dysfunction in patients with RA⁸⁻¹¹.

Statins and ACE inhibitors are 2 classes of drugs whose effects on endothelial functions have been widely investigated. Statins, which are mostly used for lipid modulation, have been shown to improve endothelial vasodilator response in patients with atherosclerosis¹⁷⁻²⁰. This beneficial effect was attributed to their antiinflammatory and immunomodulatory properties, which were independent of




Figure 1. The effect of simvastatin 20 mg daily treatment for 8 weeks of duration on flow mediated vasodilatation (endothelial-dependent vasodilatation) and glycerol trinitrate (GTN) induced vasodilatation (endothelial-independent vasodilatation). Data are mean \pm SEM. * Statistically significant.




Figure 2. The effect of quinapril 10 mg daily treatment for 8 weeks of duration on flow mediated vasodilatation (endothelial-dependent vasodilatation) and glycerol trinitrate (GTN) induced vasodilatation (endothelial-independent vasodilatation). Data are mean \pm SEM.

their cholesterol-lowering function²⁹. *Ex vivo* studies revealed that statins suppress adhesion molecules, leukocyte cytokine release, and MHC-II expression³⁰. Statins also improve the stability of the mRNA for endothelial nitric oxide synthase (eNOS), and by so doing enhance the generation of NO from the endothelium, which has a vasodilatory effect³¹. ACE inhibitors were also shown to improve

endothelial vasodilator responses through decreased levels of angiotensin II and increased levels of bradykinin and NO¹⁴. Not only longterm treatment but also acute administration of ACE inhibitors has been shown to augment endothelial-dependent vasodilatation in coronary circulation³². However, to date there are no data regarding the effects of statins and ACE inhibitors on endothelial functions in patients having chronic inflammation as in RA.

In our comparative study in patients with RA, we tested 2 groups of agents previously shown to improve endothelial functions in patients with coronary atherosclerosis. Our results showed that only simvastatin was associated with a significant improvement in endothelial-dependent vasodilatation. To our knowledge this is the first demonstration of such an improvement. Recently, Van Doornum, *et al*³³ published their results on the effects of atorvastatin 20 mg daily in patients with longterm RA. They showed a significant reduction in arterial stiffness measured by pulse-wave analysis after 12 weeks of atorvastatin treatment. Our findings confirm their results, although we observed a significant improvement with a different method.

We also observed that simvastatin caused a significant decrease in CRP and TNF- α levels, which may explain its beneficial effects on endothelial functions. Our findings are in agreement with others who predicted a significant decrease in CRP levels after statin treatment in different patient populations^{34,35}. Moreover, in a small sample size preliminary study, Abud-Mendoza, *et al* indicated that atorvastatin 20 mg daily decreased CRP levels and improved clinical status in patients with RA³⁶. Additionally, in a recent study, McCarey, *et al* investigated the effects of atorvastatin 40 mg daily in 116 patients with RA and found significantly improved clinical status measured by DAS28 and decreased CRP and IL-6 levels at the end of 6 months³⁷. Our findings are similar to these 2 studies, although we were primarily interested in endothelial functions, not in clinical improvement. In light of these studies and the fact that elevated plasma CRP level is associated with endothelial dysfunction and high mortality³⁸, it seems reasonable that drugs that decrease CRP may improve endothelial function and decrease mortality in patients under high atherosclerotic risk. From this point of view, statins seem to be an important optional class of drugs in the treatment of patients with high cardiovascular risk if their CRP-lowering effect can be confirmed in studies with large patient groups.

Circulating measures of cytokines including IL-1, IL-6, and TNF- α were also shown to increase inflammatory processes and predict cardiovascular events^{39,40}. In one study, local administration of TNF- α and IL-1 was shown to impair endothelial vasodilatation induced by bradykinin⁴¹. TNF- α also blocks the activation of eNOS, the main determinant of flow-dependent vasodilatation⁴². Recent evidence suggests that TNF- α plays a pivotal role in the initiation and progression of inflammation in both RA and atherosclero-

sis^{43,44}. Moreover, TNF- α was found to modulate hepatic synthesis of CRP⁴⁵. This interaction between 2 inflammatory markers may help to explain the decrease of TNF- α and CRP levels in our study. The effects of statins on TNF- α have been investigated, with results similar to our findings. In 2 studies, simvastatin was found to decrease TNF- α levels in hypercholesterolemic patients^{46,47}, and in another, pravastatin was observed to decrease TNF- α in human monocytes⁴⁸. Interestingly, the rapid positive effect of a TNF- α blocker, infliximab, on endothelial functions highlights the importance of TNF- α in the mechanism of atherosclerosis mediated by endothelial dysfunction in RA¹³. Supporting this observation, Hurlimann, *et al* demonstrated an improvement in endothelial functions in patients with RA after 12 weeks of treatment with infliximab¹².

Considered together, CRP and TNF- α seem to have important roles in the pathogenesis of inflammation in joints and vessel walls, and their decrease with any drug could improve inflammation in both joints and vascular endothelium. Potential dual effects in reducing inflammation and vascular risk may accrue with the use of statins in RA. As well, because endothelial reactivity of the brachial artery shows a close correlation with that seen in the coronary arteries⁴⁹, our results support the idea that statins can decrease future cardiovascular events in patients with RA.

Interestingly, quinapril showed no significant change in either endothelium-dependent or independent vasodilatation. Quinapril was chosen as an ACE inhibitor because it has been shown to have high tissue specificity for ACE, and the association of the drug with the enzyme is markedly prolonged compared with other ACE inhibitors⁵⁰. Moreover, clinical studies have shown that quinapril compared to other ACE inhibitors exerts beneficial effects in endothelial dysfunction^{15,16}. In our study, although a tendency to improvement in endothelial-dependent vasodilatation was observed in the quinapril group, this increase did not reach statistical significance. Moreover, the lack of effect on CRP or TNF- α levels in the quinapril group could partially explain the lack of efficacy. It is also possible that the lack of efficacy of quinapril may be related to improper dosage or length of treatment. Because higher doses of quinapril (20–40 mg/day) usually cause severe hypotension in a normotensive population, higher doses with ACE inhibitors might cause significant problems during the treatment period. Nevertheless, studies with higher doses would be required to determine if these groups of drugs have no significant beneficial effect on endothelial functions.

This is the first study to show that simvastatin 20 mg daily improves endothelial function in patients with RA. Its beneficial effect may be attributed to its lowering levels of CRP and TNF- α . ACE inhibition with quinapril 10 mg daily was found to have no significant effect on inflammatory markers and endothelial vasodilator response. Our data confirm the antiinflammatory effects of statins and support their

therapeutic potential for preventing cardiovascular events in patients with systemic inflammatory disease such as RA. However, because of the small number of patients studied, the results of our preliminary study also need to be supported by other studies with larger patient groups.

REFERENCES

1. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. *Arterioscler Thromb Vasc Biol* 2003;23:168-75.
2. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. *Circulation* 2000;101:1899-906.
3. Hingorani AD, Cross J, Kharbanda RK, et al. Acute systemic inflammation impairs endothelium-dependent dilatation in humans. *Circulation* 2000;102:994-9.
4. Vogel R. Measurement of endothelial function by brachial artery flow-mediated vasodilation. *Am J Cardiol* 2001;88 Suppl: 31E-34E.
5. Del Rincon, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in rheumatoid arthritis cohort not explained by traditional risk factors. *Arthritis Rheum* 2001;44:2737-45.
6. McEntegart A, Capell HA, Creran D, Rumley A, Woodward M, Lowe GD. Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. *Rheumatology Oxford* 2001;40:640-4.
7. Raza K, Thambyrajah J, Townend JN, et al. Suppression of inflammation in primary systemic vasculitis restores vascular endothelial function: lessons for atherosclerotic disease? *Circulation* 2000;102:1470-2.
8. Haensel S, Laessig G, Pistrosch F, Passauer J. Endothelial dysfunction in young patients with long-term rheumatoid arthritis and low disease activity. *Atherosclerosis* 2003;170:177-80.
9. Vaudo G, Marchesi S, Gerli R, et al. Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. *Ann Rheum Dis* 2004;63:31-5.
10. Gonzalez-Juanatey C, Testa A, Garcia-Castello A, et al. HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis. *Am J Med* 2003;114:647-52.
11. Yki-Jaervinen H, Bergholm R, Leirisalo-Repo M. Increased inflammatory activity parallels increased basal nitric oxide production and blunted response to nitric oxide in vivo in rheumatoid arthritis. *Ann Rheum Dis* 2002;62:630-4.
12. Hurlimann D, Forster A, Noll G, et al. Anti-tumor necrosis factor- α treatment improves endothelial function in patients with rheumatoid arthritis. *Circulation* 2002;106:2184-7.
13. Gonzalez-Juanatey C, Testa A, Garcia-Castello A, Garcia-Porrúa C, Llorca J, Gonzalez-Gay MA. Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor- α antibody. *Arthritis Rheum* 2004;51:447-50.
14. Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. *Circulation* 1997;95:1115-8.
15. Mancini GB, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND study. *Circulation* 1996;94:258-65.
16. Anderson TJ, Overhiser RW, Haber HE, Charbonneau F. A comparative study of four anti-hypertensive agents on endothelial function in patients with coronary artery disease [abstract]. *J Am Coll Cardiol* 1998;31:327.
17. Anderson TJ, Meredith IT, Yeung AJ, Frei B, Selwyn A, Gans P.

- The effect of cholesterol lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. *N Eng J Med* 1995;332:488-93.
18. Leung WH, Lau CP, Wong CK. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolemic patients. *Lancet* 1993;341:1496-500.
 19. Masumoto A, Hirooka Y, Hironaga K, et al. Effects of pravastatin on endothelial function in patients with coronary artery disease (cholesterol-independent effect of pravastatin). *Am J Cardiol* 2001;88:1291-4.
 20. Perticone F, Ceravolo R, Maio R, et al. Effects of atorvastatin and vitamin C on endothelial function of hypercholesterolemic patients. *Atherosclerosis* 2000;152:511-8.
 21. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of RA. *Arthritis Rheum* 1988;31:315-24.
 22. Prevoo ML, van't Hof M, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified Disease Activity Scores that include twenty-eight joint counts: development and validation. *Arthritis Rheum* 1995;38:44-8.
 23. Cortas NK, Wakid NW. Determination of inorganic nitrate in serum and urine by a kinetic cadmium-reduction method. *Clin Chem* 1990;36:1440-3.
 24. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. *Lancet* 1992;340:1111-5.
 25. Riboldi P, Gerosa M, Luzzana C, Catelli C. Cardiac involvement in systemic autoimmune diseases. *Clin Rev Allergy Immunol* 2002;23:247-61.
 26. Bacon PA, Stevens RJ, Carruthers DM, Young SP, Kitas GD. Accelerated atherogenesis in autoimmune rheumatic diseases. *Autoimmun Rev* 2002;1:338-47.
 27. Bijl M. Endothelial activation, endothelial dysfunction and premature atherosclerosis in systemic autoimmune diseases. *Neth J Med* 2003;61:273-7.
 28. Kuuliala A, Eberhardt K, Takala A, Kautiainen H, Repo H, Leirisalo-Repo M. Circulating soluble E-selectin in early rheumatoid arthritis: a prospective five year study. *Ann Rheum Dis* 2002;61:242-6.
 29. Meroni PL, Luzzana C, Ventura D. Anti-inflammatory and immunomodulating properties of statins. *Clin Rev Allergy Immunol* 2002;23:263-77.
 30. Palinski W, Napoli C. Unraveling pleiotropic effects of statins on plaque rupture. *Arterioscler Thromb Vasc Biol* 2002;22:1745-50.
 31. Bellosta S, Ferri N, Bernini F, Paoletti R, Corsini A. Non-lipid-related effects of statins. *Ann Med* 2000;32:164-76.
 32. Antony I, Lerebous G, Nitenberg A. Angiotensin-converting enzyme inhibition restores flow-dependent and cold pressor test-induced dilations in coronary arteries in hypertensive patients. *Circulation* 1996;94:3115-22.
 33. Van Doornum S, McColl G, Wicks IP. Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis. *Ann Rheum Dis* 2004;63:1571-5.
 34. Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study. *JAMA* 2001;286:64-70.
 35. Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Deveraj S. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. *Circulation* 2001;103:1933-5.
 36. Abud-Mendoza C, De La Fuente H, Cuevas-Orta E, Baranda L, Cruz-Rizo J, Gonzalez-Amaro R. Therapy with statins in patients with refractory rheumatic disease: a preliminary study. *Lupus* 2003;12:607-11.
 37. McCarey DW, McInnes IB, Madhok R, et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomized placebo-controlled trial. *Lancet* 2004;363:2015-21.
 38. Libby P, Ridker PM. Inflammation and atherosclerosis: Role of C-reactive protein in risk assessment. *Am J Med* 2004;116:9S-16S.
 39. Bacon PA, Raza K, Banks MJ, Townend J, Kitas GD. The role of endothelial cell dysfunction in the cardiovascular mortality of RA. *Int Rev Immunol* 2002;21:1-17.
 40. Blake GJ, Ridker PM. Inflammatory biomarkers and cardiovascular risk prediction. *J Intern Med* 2002;252:283-94.
 41. Bhagat K, Vallance P. Inflammatory cytokines impair endothelium dependent dilatation in human veins in vivo. *Circulation* 1997;96:3042-7.
 42. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. *Nature* 1999;399:601-5.
 43. Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. *Circ Res* 2001;89:763-71.
 44. Feldmann M, Brennan FM, Foxwell BM, Maini RN. The role of TNF alpha and IL-1 in rheumatoid arthritis. *Curr Dir Autoimmun* 2001;3:188-99.
 45. Molenaar ETH, Vaskuyl AE, Familian A, van Mierlo GJ, Dijkman BAC, Hack CE. Complement activation in patients with rheumatoid arthritis mediated in part by C-reactive protein. *Arthritis Rheum* 2001;44:997-1002.
 46. Tikiz C, Unlu Z, Tikiz H, et al. The effect of simvastatin on serum cytokine levels and bone metabolism in postmenopausal subjects: negative correlation between TNF- α and anabolic bone parameters. *J Bone Miner Metab* 2004;22:365-71.
 47. Musial J, Undas A, Gajewski P, Jankowski M, Sydor W, Szczeklik A. Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. *Int J Cardiol* 2001;77:247-53.
 48. Grip O, Janciauskiene S, Lindgren S. Pravastatin down-regulates inflammatory mediators in human monocytes in vitro. *Eur J Pharmacol* 2000;410:83-92.
 49. Anderson TJ, Uehata A, Gerhard MD, et al. Close relation of endothelial function in the human coronary and peripheral circulations. *J Am Coll Cardiol* 1995;26:1235-41.
 50. Johnston CI, Fabris B, Yamada H, et al. Comparative studies of tissue inhibition by angiotensin converting enzyme inhibitors. *J Hypertens* 1989;7:S11-S16.